Abstract
Good review practices (GRP) for drug products are a system to ensure the consistency, transparency, fairness, and objectivity of the review process. To this end, the standardized guidelines on process and procedures for the review of drug products were developed for efficient conduct of the review process, and ongoing training activities were conducted to improve the expertise level of reviewers. Since the introduction of the GRP system in 2004, the Korea Food and Drug Administration has initiated various research activities to reflect the results in the review process. Major accomplishments arising from the introduction of the GRP are as follows: (1) standardized review forms for various review areas and guidelines on considerations in reviewing drug products were developed to improve the efficiency and effectiveness of the review process; (2) the review-related regulations were newly developed or revised and guidelines were published to ensure the consistency and fairness of the review process; (3) the procedure for disclosure of review results was developed and various data and information have been disclosed to the public to improve the transparency and reliability of the review process and results; and (4) training programs for reviewers have been developed and implemented to improve the expertise level of reviewers and ensure reliable review results. In addition, a road map for the GRP system was developed, which has been systematically executed to improve the quality of the review process and confidence in the review results.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Center for Drug Evaluation and Research, Office of New Drugs. Good review practices. MAPP 6025.1, September 4, 2006.
Guidance for Reviewers and MaPPs. Pharmacology/Toxicology Review Format (FDA Guidance), Clinical Pharmacology and Biopharmaceutics NDA Review Template (FDA, Mapp 4000.4), Clinical Review Template (FDA, Mapp 6010.3). Available at: http://www.fda.gov/cder/guidance/4120fnl.pdf/cder/guidance/4120fnl.pdf; http://www.fda.gov/cder/mapp/4000.4.pdf/cder/mapp/4000.4.pdf; http://www.fda.gov/cder/mapp/6010.3.pdf/cder/mapp/6010.3.pdf.
Jeon MH. Korea Food and Drug Administration to facilitate and streamline drug review processes. More information will be made publicly available. Daily Pharma. March 19, 2004.
Korea Food and Drug Administration. Laws and regulations. Available at: http://http://www.KFDA.go.kr.
Yoo TM. Introduction to organization and job description: the Department of Drug Evaluation. Presented at the Public Forum for New Drug Review Procedures by the Korean Food and Drug Administration, Seoul, Korea, March 18, 2004.
Kim DS, Choi BK, Kim YO, Lee SJ, Lee JH, Wang SY. International harmonization on drug evaluation: establishment of good review practice system. Annual Report of KFDA. 2006;10: 295. Available at: http://www.kfda.go.kr/open_content/news/notice_view.php?menucode=103001001&seq=796/open_content/news/notice_view.php?menucode=103001001&seq=796.
Guidance for public disclosure of review reports in Korea. Available at: http://www.kfda.go.kr/open_content/data/drug_main.php?av_pg=2&menucode=104001002&opt_code=008&textfield=&keyfield=/open_content/data/drug_main.php?av_pg=2&menucode=104001002&opt_code=008&textfield=&keyfield=.
Choi B-K et al. Good review practice, disclosure of drug information. Korean SocPharma Regulatory Sci. 2006;1(1):51–56.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, YO., Park, IS., Wang, SY. et al. Development and Establishment of Good Review Practices for Drug Products in Korea. Ther Innov Regul Sci 42, 487–491 (2008). https://doi.org/10.1177/009286150804200509
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/009286150804200509